Recipharm
- 1
- 2
Recipharm expands manufacturing to meet demanding FDA requirements
Established a new, dedicated non-bacterial beta-lactam manufacturing facility in response to FDA guidance Secured a strategic partnership with an innovative biopharma company seeking rapid regulatory compliance Developed a scalable platform in Bengaluru, India, with capacity available to support future customers with similar regulatory needs. 26 January 2026 -- Stockholm, Sweden -- Recipharm, a leading global contract...
Infant Bacterial Therapeutics AB secures partnership with Recipharm Advanced Bio for commercial production of drug substance
IBP-9414 targets mortality and gastrointestinal injury in premature infants With Breakthrough Therapy designation for gastro-intestinal mortality and Rare Paediatric Disease designations, IBP-9414 is on an accelerated path to commercialisation PPQ (Process Performance Qualification) runs for IBP-9414 begin at Recipharm Advanced Bio’s Cuxhaven site, marking a major milestone on the path to regulatory approval. 1 December...
Telomir and Mira Pharmaceuticals advance through key development milestones with Recipharm support
Telomir-1 has now entered GMP preparation, and Ketamir-2 has completed the Phase 1 SAD stage, reflecting steady advancement of both programmes These milestones mark tangible progress in development and demonstrate the effectiveness of the ongoing collaboration Recipharm provides end-to-end support, including API synthesis, process development and GMP manufacturing, enabling seamless transition from research into clinical...
University of Oxford and ReciBioPharm expand strategic collaboration in fight against malaria
Expands the collaboration to manufacture two malaria vaccine candidates (R78C and RH5.1) for Phase 1/2 clinical trials Delivers the sixth malaria vaccine candidate for the University of Oxford Provides drug substance, drug product and large-scale fill and finish expertise through ReciBioPharm, Recipharm’s Advanced Biologics division Contributes to global malaria control and elimination efforts, addressing a...
Recipharm expands aseptic filling capabilities for process development, pilot scale and clinical supply
GMP aseptic filling under isolator conditions, for process development, pilot scale and clinical supply projects Supports various containers, including pre-filled syringes and liquid vials Complements existing sterile development and commercial capabilities 5 February 2025 – Recipharm, a leading global contract development and manufacturing organisation (CDMO), has announced that a new modular sterile filling system specifically...
Spektus Pharma and Recipharm Announce Strategic Partnership to Develop and Supply CNS Medicines Using Flexitab™ Oral Drug Delivery Platform
22 January 2025 -- Montreal, Canada -- Spektus Pharma, an innovator in value added medicine development, and Recipharm, a leading global contract development and manufacturing organization, have entered into a strategic partnership, through Recipharm’s segment responsible for managing its intellectual property. Together, the companies will jointly develop and supply a portfolio of novel Central Nervous...
Recipharm’s full range Oral Solid Dosage (OSD) capabilities meet growing industry demands
Full range OSD development and manufacturing capabilities from orphan drugs to blockbusters High potency manufacturing capabilities expansion Introduction of ReciPredict platform to accelerate product development and de-risk tech transfer API capabilities from route scouting to large scale synthesis 19 November 2024 – Recipharm, a leading global contract development and manufacturing organisation (CDMO), has significantly enhanced...
Recipharm attains major sustainability milestones
Approval of ambitious Greenhouse Gas emission reduction targets by SBTi Commitment to renewable electricity sourcing to 100.0% by 2024 and to 42.1% GHG emission reduction (Scope 1 and 2) by 2030 Elevated CDP Climate rating to B level. 26 March 2024 -- Stockholm, Sweden -- Recipharm, a global leader in contract development and manufacturing, has...
ReciBioPharm and GeneVentiv Therapeutics partner to advance first AAV-based gene therapy for haemophilia patients with inhibitors
13 March 2024 -- Stockholm, Sweden -- ReciBioPharm, the advanced and emerging therapies business unit of Recipharm, has announced a collaboration agreement with GeneVentiv Therapeutics, a pre-clinical gene therapy company, to advance development of an Adeno-Associated Virus (AAV)-based universal gene therapy for haemophilia, and the first to treat haemophilia patients with inhibitors. On average 30%...
Recipharm, Medspray and Resyca enter into exclusive license agreement to develop nasally-delivered drug products using proprietary soft mist technology
Partnership will help bring breakthroughs in the nasal delivery of fragile biologics and small molecules to market 23 January 2023 -- Stockholm, Sweden -- Recipharm, a leading contract development and manufacturing organisation (CDMO), is pleased to announce an exclusive licence and collaboration agreement with Medspray and Resyca, to develop soft mist nasal delivery devices for...
- 1
- 2
